Stockscreener 앱 받기
7.055
1.44%
0.10
시간 외 거래:
7.38
0.325
+4.61%
전일 마감가:
$6.955
열려 있는:
$6.9
하루 거래량:
129.77K
Relative Volume:
1.79
시가총액:
$83.95M
수익:
$123.24M
순이익/손실:
$136.00K
주가수익비율:
-352.75
EPS:
-0.02
순현금흐름:
$-148.99M
1주 성능:
-26.74%
1개월 성능:
-34.19%
6개월 성능:
-50.68%
1년 성능:
-65.75%
1일 변동 폭
$6.64
$7.2385
1주일 범위
$6.64
$9.73
52주 변동 폭
$6.64
$30.60
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
MCRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
7.055 | 83.95M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
MCRB: Seres Therapeutics' Price Target Raised by Chardan Capital | MCRB Stock News - GuruFocus
Chardan cuts Seres Therapeutics stock rating to neutral - Investing.com
Seres Therapeutics: Q1 Earnings Snapshot - Norwalk Hour
Seres Therapeutics Reports Positive Q1 2025 Results - TipRanks
Seres Therapeutics’ Positive Earnings Call: Progress and Challenges - TipRanks
Transcript : Seres Therapeutics, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Earnings call transcript: Seres Therapeutics Q1 2025 sees net income boost - Investing.com Nigeria
Seres Therapeutics, Inc. SEC 10-Q Report - TradingView
Seres Therapeutics Advances SER-155 Program with FDA Submission - TipRanks
Seres Therapeutics (MCRB) Targets Advancement of SER-155 in Clinical Development | MCRB Stock News - GuruFocus
Seres Therapeutics Inc Qtrly EPS $3.76 - marketscreener.com
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 - The Globe and Mail
Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $80.00 - Defense World
Seres Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
5 Best Microbiome Companies (May 2025) - Securities.io
Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com - Defense World
Seres Therapeutics Reveals Game-Changing Biomarkers for IBD Treatment, Seeks Development Partners - Stock Titan
Seres Therapeutics (MCRB) to Unveil New Findings at 2025 Digesti - GuruFocus
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases - The Manila Times
Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Weak at 0.70, Down -2.90 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - Defense World
MCRB Stock Update: Seres Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
Seres Therapeutics Inc (MCRB) expanding its growth trajectory ahead - Sete News
Seres Therapeutics Reveals Q1 2025 Results: Live Biotherapeutics Pioneer Updates Growth Strategy - Stock Titan
Seres Therapeutics enacts 1-for-20 reverse stock split By Investing.com - Investing.com India
Seres Therapeutics enacts 1-for-20 reverse stock split - Investing.com
JP Morgan downgrades Seres Therapeutics Inc (MCRB) rating to an Underweight - knoxdaily.com
Oppenheimer Adjusts Seres Therapeutics Price Target to $5 From $9, Maintains Outperform Rating - marketscreener.com
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023 - marketscreener.com
Upcoming Stock Splits This Week (April 21 to April 25) – Stay Invested - The Globe and Mail
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround - NewsBreak: Local News & Alerts
MCRB stock touches 52-week low at $0.46 amid market challenges By Investing.com - Investing.com South Africa
MCRB stock touches 52-week low at $0.46 amid market challenges - Investing.com
Seres Therapeutics enacts stock incentive plan and reverse split By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Seres Therapeutics enacts stock incentive plan and reverse split - Investing.com
Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at StockNews.com - Defense World
Seres Therapeutics Inc (NASDAQ: MCRB): Blank Check On Growth? - stocksregister.com
Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target at $4.00 - Defense World
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
0.15%
자본화:
|
볼륨(24시간):